Cargando…

Effect of high-intensity interval training on cardiovascular disease risk factors and body composition in psoriatic arthritis: a randomised controlled trial

BACKGROUND: Psoriatic arthritis (PsA) is associated with an accumulation of cardiovascular disease (CVD) risk factors. The aim of this study was to evaluate the effect of high-intensity interval training (HIIT) on CVD risk factors in patients with PsA. METHODS: We randomly assigned 61 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thomsen, Ruth Stoklund, Nilsen, Tom Ivar Lund, Haugeberg, Glenn, Bye, Anja, Kavanaugh, Arthur, Hoff, Mari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Psoriatic Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203095/ https://www.ncbi.nlm.nih.gov/pubmed/30402265 http://dx.doi.org/10.1136/rmdopen-2018-000729

Ejemplares similares

Change in cardiovascular risk factors in patients who develop psoriatic arthritis: longitudinal data from the Nord-Trøndelag Health Study (HUNT)
por: Gulati, Agnete Malm, et al.
Publicado: (2018)

Osteoporosis in psoriatic arthritis: a cross-sectional study of an outpatient clinic population
por: Gulati, Agnete Malm, et al.
Publicado: (2018)

Bone mineral density in patients with psoriatic arthritis: data from the Nord-Trøndelag Health Study 3
por: Gulati, Agnete Malm, et al.
Publicado: (2017)

Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era
por: Haugeberg, Glenn, et al.
Publicado: (2020)

Achilles enthesitis defined by ultrasound is not associated with clinical enthesitis in patients with psoriatic arthritis
por: Michelsen, Brigitte, et al.
Publicado: (2017)

Changes of inflammation in patients with psoriatic arthritis after high intensity interval training assessed by ultrasound and MRI, a randomized controlled trial
por: Thomsen, Ruth Stoklund, et al.
Publicado: (2023)

Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J, et al.
Publicado: (2018)

The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies
por: Kavanaugh, Arthur, et al.
Publicado: (2019)

Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis
por: Husni, M. Elaine, et al.
Publicado: (2020)

Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial
por: Mease, Philip J, et al.
Publicado: (2018)

Ustekinumab Treatment and Improvement of Physical Function and Health‐Related Quality of Life in Patients With Psoriatic Arthritis
por: Rahman, Proton, et al.
Publicado: (2016)

Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
por: Helliwell, Philip S, et al.
Publicado: (2020)

Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
por: Mease, Philip J., et al.
Publicado: (2020)

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial
por: Mease, Philip J, et al.
Publicado: (2017)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
por: Helliwell, Philip S, et al.
Publicado: (2022)

Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty‐Four of the GO‐VIBRANT Study
por: Kavanaugh, Arthur, et al.
Publicado: (2017)

Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2
por: McInnes, Iain B, et al.
Publicado: (2019)

Psoriatic arthritis: an evolving matter
por: Wendling, Daniel
Publicado: (2015)

Distinguishing rheumatoid arthritis from psoriatic arthritis
por: Merola, Joseph F, et al.
Publicado: (2018)

Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis
por: Huynh, D H, et al.
Publicado: (2017)

Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies
por: Gladman, Dafna D, et al.
Publicado: (2018)

Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia
por: Zabotti, Alen, et al.
Publicado: (2019)

Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set
por: Kalyoncu, Umut, et al.
Publicado: (2016)

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
por: Mease, Philip J, et al.
Publicado: (2021)

Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis
por: Wervers, Kim, et al.
Publicado: (2018)

Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo‐Controlled Study
por: Kavanaugh, Arthur, et al.
Publicado: (2016)

Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double‐Blind Withdrawal Study
por: Coates, Laura C., et al.
Publicado: (2021)

What makes psoriatic and rheumatoid arthritis so different?
por: Veale, Douglas James, et al.
Publicado: (2015)

Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis
por: Zhang, Hanzhe, et al.
Publicado: (2021)

Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase III Trial
por: Kavanaugh, Arthur, et al.
Publicado: (2015)

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
por: Baraliakos, Xenofon, et al.
Publicado: (2021)

Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination
por: Strand, Vibeke, et al.
Publicado: (2021)

Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study
por: Coates, Laura C., et al.
Publicado: (2022)

Patient-Reported Outcomes and the Association With Clinical Response in Patients With Active Psoriatic Arthritis Treated With Golimumab: Findings Through 2 Years of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Kavanaugh, Arthur, et al.
Publicado: (2013)

High burden of polypharmacy and comorbidity in persons with psoriatic arthritis: an analysis of claims data, stratified by age and sex
por: Albrecht, Katinka, et al.
Publicado: (2023)

Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis: an observational nationwide study
por: Lindström, Ulf, et al.
Publicado: (2023)

Real-world burden of comorbidities in US patients with psoriatic arthritis
por: Shah, Kamal, et al.
Publicado: (2017)

Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis
por: Wade, Sarah M, et al.
Publicado: (2019)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2019)

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis
por: van der Heijde, Désirée, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_poosut4kql3g3vp5fl9i2ehca5